Lu Wang

Dr. Lu Wang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSamuel W. Brady
Samuel W. Brady
YLYanling Liu
Yanling Liu
XMXiaotu Ma
Xiaotu Ma
AGAlexander M. Gout
Alexander M. Gout
KHKohei Hagiwara
Kohei Hagiwara
JZJinghui Zhang
Jinghui Zhang
Neuroblastoma is a pediatric malignancy with heterogeneous clinical outcomes. To better understand neuroblastoma pathogenesis, here we analyze whole-genome, whole-exome and/or transcriptome data from 702 neuroblastoma samples. Forty percent of samples harbor at least one recurrent driver gene alteration and most aberrations, including MYCN, ATRX, and TERT alterations, differ in frequency by age. MYCN alterations occur at median 2.3 years of age, TERT at 3.8 years, and ATRX at 5.6 years. COSMIC mutational signature 18, previously associated with reactive oxygen species, is the most common cause of driver point mutations in neuroblastoma, including most ALK and Ras-activating variants. Signature 18 appears early and is continuous throughout disease evolution. Signature 18 is enriched in neuroblastomas with MYCN amplification, 17q gain, and increased expression of mitochondrial ribosome and electron transport-associated genes. Recurrent FGFR1 variants in six patients, and ALK N-terminal structural alterations in five samples, identify additional patients potentially amenable to precision therapy.

1 May 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
GZGuo Zhu
Guo Zhu
RBRyma Benayed
Ryma Benayed
CHCaleb Ho
Caleb Ho
KMKerry Mullaney
Kerry Mullaney
PSPurvil Sukhadia
Purvil Sukhadia
MHMeera R. Hameed
Meera R. Hameed

11 January 2024 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MUMasayuki Umeda
Masayuki Umeda
JMJing Ma
Jing Ma
TWTamara Westover
Tamara Westover
YNYonghui Ni
Yonghui Ni
GSGuangchun Song
Guangchun Song
JKJeffery M. Klco
Jeffery M. Klco
Recent studies on pediatric acute myeloid leukemia (pAML) have revealed pediatric-specific driver alterations, many of which are underrepresented in the current classification schemas. To comprehensively define the genomic landscape of pAML, we systematically categorized 887 pAML into 23 mutually distinct molecular categories, including new major entities such as UBTF or BCL11B, covering 91.4% of the cohort. These molecular categories were associated with unique expression profiles and mutational patterns. For instance, molecular categories characterized by specific HOXA or HOXB expression signatures showed distinct mutation patterns of RAS pathway genes, FLT3 or WT1, suggesting shared biological mechanisms. We show that molecular categories were strongly associated with clinical outcomes using two independent cohorts, leading to the establishment of a new prognostic framework for pAML based on these updated molecular categories and minimal residual disease. Together, this comprehensive diagnostic and prognostic framework forms the basis for future classification of pAML and treatment strategies.

29 March 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
JBJan Bařinka
Jan Bařinka
ZHZunsong Hu
Zunsong Hu
LWLu Wang
Lu Wang
DWDavid A. Wheeler
David A. Wheeler
DRDelaram Rahbarinia
Delaram Rahbarinia
CMCharles G Mullighan
Charles G Mullighan

26 August 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
NRNatasha Rekhtman
Natasha Rekhtman
STSam E. Tischfield
Sam E. Tischfield
CAChristopher Febres Aldana
Christopher Febres Aldana
JLJake June-Koo. Lee
Jake June-Koo. Lee
JCJason C. Chang
Jason C. Chang
CRCharles M. Rudin
Charles M. Rudin
Small cell lung carcinoma (SCLC) is a highly aggressive malignancy that is typically associated with tobacco exposure and inactivation of RB1 and TP53 genes. Here, we performed detailed clinicopathologic, genomic, and transcriptomic profiling of an atypical subset of SCLC that lacked RB1 and TP53 co-inactivation and arose in never/light smokers. We found that most cases were associated with chromothripsis—massive, localized chromosome shattering—recurrently involving chromosome 11 or 12 and resulting in extrachromosomal amplification of CCND1 or co-amplification of CCND2/CDK4/MDM2, respectively. Uniquely, these clinically aggressive tumors exhibited genomic and pathologic links to pulmonary carcinoids, suggesting a previously uncharacterized mode of SCLC pathogenesis via transformation from lower-grade neuroendocrine tumors or their progenitors. Conversely, SCLC in never-smokers harboring inactivated RB1 and TP53 exhibited hallmarks of adenocarcinoma-to-SCLC derivation, supporting two distinct pathways of plasticity-mediated pathogenesis of SCLC in never-smokers. Significance: Here, we provide the first detailed description of a unique SCLC subset lacking RB1/TP53 alterations and identify extensive chromothripsis and pathogenetic links to pulmonary carcinoids as its hallmark features. This work defines atypical SCLC as a novel entity among lung cancers, highlighting its exceptional histogenesis, clinicopathologic characteristics, and therapeutic vulnerabilities. See related commentary by Nadeem and Drapkin, p. 8

23 October 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
KFKaren Fritchie
Karen Fritchie
LWLu Wang
Lu Wang
ZYZhaohong Yin
Zhaohong Yin
JNJoy Nakitandwe
Joy Nakitandwe
DHDale Hedges
Dale Hedges
Armita BahramiArmita Bahrami
Armita Bahrami